Scienture Holdings, Inc. — Filing identity and period
Important identity discrepancy: The supplied filing is TRxADE HEALTH, INC. (ticker MEDS), not Scienture Holdings, Inc. It is a unaudited Form 10-Q for the quarter ended September 30, 2021, covering the three and nine months ended on that date. Verify the issuer before relying on this summary.
TRxADE describes itself as a health-services technology company operating a pharmaceutical marketplace, wholesaling and pharmacy businesses, and telehealth and health-passport offerings. The company changed its name to TRxADE HEALTH, INC. effective June 1, 2021.
Financial performance and position
| Metric | Q3 2021 | Q3 2020 | Nine months 2021 | Nine months 2020 |
|---|---|---|---|---|
| Revenue | $2.55 million | $6.33 million | $7.50 million | $15.13 million |
| Gross profit | $1.28 million | $1.93 million | $3.51 million | $5.57 million |
| Gross margin | 50% | 31% | 47% | 37% |
| Net income (loss) | $(1.30) million | $138,391 | $(4.53) million | $(223,893) |
| Loss per share, basic and diluted | $(0.16) | $0.02 | $(0.56) | $(0.03) |
- For the nine-month period, revenue fell 50.4%; management attributed the decline mainly to non-recurring 2020 PPE sales and reduced platform activity amid generic-drug supply constraints. Gross margin improved as the sales mix shifted away from lower-margin PPE and toward higher-margin platform revenue.
- Nine-month operating expenses included $1.23 million of inventory investment losses. General and administrative expense, excluding stock compensation, rose to $6.34 million from $4.08 million, primarily due to technology development, marketing and legal costs. Bad-debt expense was $616,215, including a past-due $630,000 customer note receivable.
- Cash was $3.57 million at September 30, 2021, down from $5.92 million at December 31, 2020. Working capital was $4.53 million, down from $8.38 million. Current assets were $5.19 million and current liabilities $654,861.
- Cash used in operating activities was $2.14 million for the nine months, versus $1.50 million in 2020. Investing cash flow was zero; financing cash flow was a use of $208,178, including repayment of a $225,000 related-party note. No related-party debt remained at quarter-end. Lease liabilities totaled $305,505; the filing reports no other long-term debt balance.
- Total assets were $5.51 million and stockholders’ equity was $4.62 million at September 30, 2021. Shares outstanding were 8,166,457 at quarter-end and October 25, 2021.
Changes, outlook and material matters
- Compared with 2020, the company moved from quarterly profit to a quarterly loss and reported a substantially larger nine-month loss. Lower sales and increased operating costs, bad debt and inventory-related charges contributed.
- Management estimated general and administrative and working-capital requirements of approximately $9 million for October 2021 through September 2022, and said it expected to fund these with cash on hand and operating revenue. It said available resources were sufficient for the foreseeable future, while acknowledging possible future financing needs and no assurance of favorable or available funding.
- An at-the-market equity program permits sales of up to $9 million, with a 2% agent commission. No shares had been sold under it as of the filing. The board also authorized a $1 million share repurchase program; none had been repurchased by September 30, 2021.
- Management said COVID-19 had not materially harmed results to date, but cited pharmaceutical supply interruptions, staffing and technology-outsourcing constraints, and uncertainty about future effects. It also noted that demand for the MedCheks health passport may not develop and that Bonum Health Hub deployment was not expected to proceed; hubs were written off.
- Two disputed inventory-purchase deposits—$500,000 and $581,250—were written off as losses. Related recovery litigation remained unresolved; the Malaysian summary-judgment application was denied and a trial date was pending. The company also reported a separate customer note collection dispute and litigation alleging claims of approximately $450,000; management assessed the likelihood of material loss in that case as remote.
- Disclosure controls and procedures were deemed ineffective at September 30, 2021. Management cited material weaknesses involving insufficient written accounting/reporting policies and ineffective period-end financial reporting controls, and described remediation efforts. The filing reported no material changes to internal control during the quarter.
- Management gave no specific revenue or earnings guidance. It cautioned that quarterly comparisons may be unreliable because of non-recurring product sales. COVID-19, supply availability, inventory write-downs, customer collections, financing access, health-passport adoption and control weaknesses remain notable risks.
Investor verification priorities
- Confirm the correct issuer: the filing identifies TRxADE HEALTH, INC., although the request identifies Scienture Holdings, Inc.
- Check the cash-flow and revenue-change figures against the financial statements: the MD&A reports a cash decrease of $2,374,689, while the statements imply $2,347,689; the MD&A also gives a Q3 revenue decrease of $3,787,223, while the reported revenues imply $3,782,223.
- Track collection prospects and timing for the $630,000 customer note and the two written-off inventory deposits, including litigation outcomes and any recoveries.
- Assess cash burn against the stated $9 million forward expense estimate, and monitor any ATM sales, dilution, or changes in liquidity.
- Evaluate whether pharmaceutical supply constraints ease, whether newer telehealth and health-passport initiatives gain customers, and whether identified financial-reporting weaknesses are remediated.